Central Dopaminergic Activity Influences Metabolic Parameters in Healthy Men

Abstract

Background/Aims: Central dopaminergic activity is probably linked to regulation of glucose and lipid metabolism and weight maintenance. The aim of our study was to evaluate the relationship between central dopaminergic activity measured using the apomorphine challenge test and metabolic parameters in healthy men. Methods: Forty-two healthy men (average age 43.5 ± 7.4 years, body mass index, BMI, 27.4 ± 5.7) were examined anthropometrically and biochemically (glycemia, lipids, glycated hemoglobin). Central dopaminergic activity was assessed as the area under the curve (AUC) of prolactin (PRL) and growth hormone (GH) responses to the apomorphine challenge test after sublingual administration of apomorphine in a dose of 0.033 mg/kg. Insulin resistance was quantified by calculation of glucose disposal and metabolic clearance rate during a euglycemic hyperinsulinemic clamp on two insulin levels (1 and 10 mIU/kg/min). Linear regression was used for statistical analysis. Results: Hormonal responses correlated negatively with age (for AUC/GH r = -0.33; p = 0.031) and BMI (AUC/GH r = -0.41; p = 0.007). After adjustment for age and BMI, a statistically significant negative correlations between AUC/PRL and total cholesterol (r = -0.41; p = 0.007), AUC/GH and HbA1c (r = -0.37; p = 0.016) and AUC/GH and HOMA (homeostasis model assessment; r = -0.345; p = 0.025) were observed. Conclusion: Central dopaminergic activity declines with age and BMI. Higher total cholesterol, glycated hemoglobin and insulin resistance parameters are connected with lower central dopamine tone.

Physical Comorbidities in Depression Co-Occurring with Anxiety: A Cross Sectional Study in the Czech Primary Care System

“…However, there is also a possibility that depression and physical disorders might have a shared origin to some extent. This hypothesis is supported by our previous studies which demonstrated that the activity of serotonin and other monoamines in brain are directly influencing insulin sensitivity in the periphery [ 35 , 36 ]. This association between central monoaminergic activity and peripheral metabolic parameters could mediate the clinically highly relevant association between type II diabetes mellitus and depression [ 26 ].…”

COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV

“…However, COMT activity produces a precursor to homocysteine, which may increase risk of cardiovascular disease, and Val carriers have significantly higher blood levels of RUNNING HEAD: HIV, COMT, and Neurocognitive Impairment 6 total homocysteine than Met homozygotes [35][36][37] . Furthermore, lower central DA tone has been linked to obesity and markers of metabolic syndrome, and DA receptor neurotransmission is reduced in obese humans and animals [38][39][40] .…”

Features of Treatment of Hypertensive Patients with Concomitant Obesity: Unknown about the Known

“…Згідно з дослідженнями Brunerova L., Potockova J., Horacek J., Andel M. (2013), пригнічення функціонального стану дофамінової системи спостерігається з віком та підвищенням ІМТ. Підвищення рівня загального холестерину (ЗХС), глікозильованого гемоглобіну пов'язано зі зниженням дофамінового тонусу [10,22].…”

“…Це також узгоджується із спостереженнями, в яких застосування нейролептиків, які є антагоністами ДР, часто супроводжуються збільшенням споживання їжі та зростанням маси тіла, унаслідок чого виникає ожиріння, метаболічний синдром, що є серйозною проблемою для таких пацієнтів та призводить до скорочення життя внаслідок серцево-судинних подій [10,21,22,23]. У ретроспективному дослідженні 483 хворих на паркінсонізм, що приймали леводопу, порівнювали із 178 пацієнтами, які не приймали цей дофаміноміметик.…”